gene

SNCA

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SNCA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

3067Connections

3Hypotheses

9Analyses

50Outgoing

50Incoming

6Experiments

10Debates

Summary

SNCA is a gene implicated in neurodegeneration research. Key relationships include: interacts with, associated with, activates. Associated with AD, ALI, ALS. Connected to 983 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	SNCA
Full Name	Alpha-Synuclein
Chromosome	4q22.1
Protein Type	Structural Protein
Target Class	Structural Protein
Function	Immunotherapy targeting alpha-synuclein aggregates or small molecules preventing aggregation
Mechanism of Action	Immunotherapy targeting alpha-synuclein aggregates or small molecules preventing aggregation
Primary Expression	Substantia nigra, Cerebral cortex, Presynaptic terminals
Druggability	Medium (0.49)
Clinical Stage	Phase II
Pathways	Akt, Alpha-Synuclein, Autophagy, Cell Cycle, Epigenetic
UniProt ID	P37840
NCBI Gene ID	6622
Ensembl ID	ENSG00000145335
OMIM	163890
GeneCards	SNCA
Human Protein Atlas	SNCA
Associated Diseases	AD, Aging, ALI, Alpha-Synucleinopathies, Als
Known Drugs/Compounds	ACI-7104.056, AFFITOPE PD01A, ASO, Cinpanemab, D-520, levodopa
Interactions	ABCA7, ABCD3, ACETYL-COA, ACLY, aco2, ACO2
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Physiological SCFAs may reduce alpha-synuclein bur Neuronal Subtype-Specific Alpha-Synuclein Expressi Sulfated glycans and metal-binding CSF proteins br
KG Connections	3065 knowledge graph edges
Databases	GeneCards HPA STRING

🧬 3D Structure Comparison — SNCA Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

1XQ8 — X-ray / Cryo-EM

🔮 AI Predicted Structure

P37840 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (12)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    SNCA["SNCA"] -->|"modulates"| calcium["calcium"]
    SNCA["SNCA"] -->|"associated"| neurodegeneration["neurodegeneration"]
    SNCA["SNCA"] -->|"interacts"| DRD2["DRD2"]
    SNCA["SNCA"] -->|"interacts"| HSPA1A["HSPA1A"]
    SNCA["SNCA"] -->|"interacts"| DNMT1["DNMT1"]
    SNCA["SNCA"] -->|"encodes"| alpha_synuclein["alpha_synuclein"]
    DRD2_1["DRD2"] -->|"interacts"| SNCA["SNCA"]
    HSPA1A_2["HSPA1A"] -->|"interacts"| SNCA["SNCA"]
    DNMT1_3["DNMT1"] -->|"interacts"| SNCA["SNCA"]
    TLR4["TLR4"] -->|"interacts"| SNCA["SNCA"]
    style SNCA fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (1540)

Target	Relation	Type	Str
ALPHA_SYNUCLEIN	encodes	protein	1.00
alpha_synuclein	encodes	protein	1.00
Dementia	associated_with	disease	1.00
alpha-synuclein	expresses	protein	1.00
dementia with Lewy bodies	implicated_in	disease	1.00
Lewy bodies	part_of	pathway	1.00
Α-SYNUCLEIN	encodes	protein	0.99
Lewy body pathology	associated_with	phenotype	0.98
Lewy Bodies	biomarker_for	biomarker	0.98
Parkinson Disease	associated_with	disease	0.95
Synucleinopathies	implicated_in	disease	0.95
Lewy Bodies	involved_in	phenotype	0.95
Parkinson's Disease with Dementia	associated_with	disease	0.95
Amyloid Formation	involved_in	process	0.95
MTOR	activates	protein	0.95
Parkinson Disease	risk_factor_for	disease	0.95
MIRO1	upregulates	protein	0.95
Parkinson's Disease	component_of	disease	0.95
Parkinson Disease	biomarker_for	disease	0.95
Parkinson'S Disease	implicated_in	disease	0.95
PARKINSON'S DISEASE	associated_with	gene	0.95
Synucleinopathies	involved_in	disease	0.95
alpha-synuclein	produces	protein	0.95
Parkinson'S Disease With Dementia	involved_in	disease	0.95
Parkinson's Disease	risk_factor_for	disease	0.95
CD4 T Cell Activation	activates	process	0.95
Dementia with Lewy Bodies	implicated_in	disease	0.95
Multiple System Atrophy	implicated_in	disease	0.95
alpha-synuclein aggregation	involved_in	process	0.95
Lewy Bodies	contributes_to	biomarker	0.95
Parkinson	associated_with	disease	0.95
Dementia With Lewy Bodies	implicated_in	disease	0.95
Alpha-Synucleinopathies	causes	disease	0.95
Lewy Body Formation	involved_in	process	0.95
Als	associated_with	disease	0.95
Inflammatory Response	associated_with	process	0.95
Parkinson's Disease	causes	disease	0.95
Neuronal α-synuclein Disease	risk_factor_for	disease	0.95
Parkinson's Disease	associated_with	disease	0.95
Microglial Autophagy	associated_with	process	0.95
Parkinson's Disease	involved_in	disease	0.95
ALPHA-SYNUCLEIN	encodes	protein	0.95
Parkinson'S Disease	associated_with	disease	0.95
Parkinson'S Disease	biomarker_for	disease	0.95
Parkinson'S Disease	causes	disease	0.95
Lewy bodies	causes	phenotype	0.95
PARKINSON'S DISEASE	involved_in	disease	0.95
Lewy Bodies	associated_with	biomarker	0.95
Parkinson'S Disease	involved_in	disease	0.95
Synucleinopathies	causes	disease	0.95

Incoming (1527)

Source	Relation	Type	Str
entities-dna-methylation	associated_with	wiki	0.00
NEURODEGENERATION	associated_with	gene	1.00
AMYLOID	associated_with	gene	1.00
PARKINSON'S DISEASE	associated_with	gene	1.00
TAU	associated_with	gene	1.00
ALZHEIMER'S DISEASE	associated_with	gene	1.00
MICROGLIA	associated_with	gene	1.00
D-520	targets	drug	0.95
Microglia	cleaves	cell_type	0.95
Short-Chain Fatty Acids	modulates	compound	0.95
ATC161	degrades	drug	0.95
AUTOTAC	targets	mechanism	0.95
Microglia	degrades	cell_type	0.95
LAG3	binds	gene	0.95
Rmab38E2-Scfv8D3	targets	drug	0.95
Rna G-Quadruplex	promotes	compound	0.95
Autophagy-Lysosomal Pathway	interacts_with	pathway	0.92
brain-derived extracellular vesicles	mediates	compound	0.90
NEURON	contributes_to	cell_type	0.90
Csga	associated_with	protein	0.90
Antisense Oligonucleotide Therapy	downregulates	drug	0.90
h-b7ab85b6	targets_gene	hypothesis	0.90
h-2e7eb2ea	targets_gene	hypothesis	0.90
PBT434	inhibits	compound	0.90
h-74777459	targets_gene	hypothesis	0.90
Synucleinopathies	associated_with	disease	0.90
h-072b2f5d	targets_gene	hypothesis	0.90
Autophagy	degrades	process	0.90
SncaEnh+37	regulates	structure	0.90
SDA-2026-04-01-gap-20260401-225155	targets	analysis	0.90
Lactococcus Lactis Mg1363-Pmg36E-Glp-1	associated_with	drug	0.90
ANTISENSE OLIGONUCLEOTIDES	downregulates	drug	0.90
Chaperone-Mediated Autophagy	mediates	pathway	0.90
PAP	co-deleted/mutated	gene	0.90
Impaired Degradation	causes	mechanism	0.90
Prasinezumab	targets	drug	0.90
MEDI1341	targets	drug	0.90
UB-312	targets	drug	0.90
Lu Af82422	targets	drug	0.90
PD03A	targets	drug	0.90
Cinpanemab	targets	drug	0.90
AFFITOPE PD01A	targets	drug	0.90
Microglial Autophagy Disruption	causes	process	0.90
ACI-7104.056	targets	drug	0.90
Motor Deficits	associated_with	phenotype	0.88
ASO	inhibits	drug	0.87
GBA1	regulates	gene	0.85
Vinpocetine	downregulates	drug	0.85
Macroautophagy	degrades	process	0.85
Astrocyte Phagocytosis	involved_in	phenotype	0.85

Targeting Hypotheses (3)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Physiological SCFAs may reduce alpha-synuclein burden primar	0.650	neurodegeneration	Do physiological concentrations of SCFAs
Neuronal Subtype-Specific Alpha-Synuclein Expression Normali	0.571	neurodegeneration	Which cell types show the most significa
Sulfated glycans and metal-binding CSF proteins brace alpha-	0.489	neurodegeneration	Which specific CSF molecular components

Mentioning Analyses (9)

Scientific analyses that reference this entity

Experiments (6)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Model	Status	Est. Cost
Long-term perampanel treatment in A53T BAC-SNCA mice with PFF injectio	validation	Lewy body disease	0.950	A53T BAC-SNCA transgenic mice	proposed	N/A
PFF uptake in primary hippocampal neurons with inhibitors	exploratory	Lewy body disease	0.900	mouse primary hippocampal neur	proposed	N/A
Longitudinal TLR2 reporter gene study in α-synuclein mice	validation	Parkinson's disease	0.900	Thy1.2-α-synuclein transgenic	proposed	N/A
Dexamethasone treatment study in α-synuclein mice	validation	Parkinson's disease	0.850	Thy1.2-α-synuclein transgenic	proposed	N/A
PFF clearance kinetics in Snca knockout mice	validation	Lewy body disease	0.800	Snca knockout mice	proposed	N/A
TLR expression in α-synuclein overexpressing mice	validation	Parkinson's disease	0.800	mice overexpressing human α-sy	proposed	N/A

Related Papers (12)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Meta-analysis of mRNA dysregulation associated with Parkinson's disease and othe [PMID:41183391]	Lin Aung T, Aung YW, Shi X	Biomed Phys Eng Express	2026	1
A human striatal-midbrain assembloid model of alpha-synuclein propagation. [PMID:40919647]	Tran HD, Shin MK, Yeo XY, Jung S, Junaid	Brain	2026	0
Neuronal titration of Snca via enhancer disruption mitigates disease onset in a [PMID:41496593]	Boyd RJ, Kho AR, McClymont SA, Loftus SK	Brain	2026	0
Perampanel Blocks Transsynaptic α-Synuclein Propagation and Neurodegeneration in [PMID:41508763]	Ueda J, Uemura N, Chang J, Hirato T, Ish	Mov Disord	2026	0
Analysis of α-synuclein seed amplification assay in carriers of GBA1 and LRRK2 p [PMID:41574889]	Fraser KB, Mirelman A, Mabrouk OS, Omer	J Parkinsons Dis	2026	0
Aberrant Protein S-Nitrosylation Mimics the Effect of Rare Genetic Mutations in [PMID:41635116]	Wang Y, Lipton SA	J Neurochem	2026	0
SNCA triplication disrupts proteostasis and extracellular architecture prior to [PMID:41698927]	Statoulla E, Zafeiri M, Chalkiadaki K, V	NPJ Parkinsons Dis	2026	0
Gene therapy targeting synaptopathy linked with Alzheimer's and Parkinson's dise [PMID:41730496]	Panda SP, Saraswat N, Singh V	Neuroscience	2026	0
Degradation of alpha-synuclein/SNCA mRNA by RNautophagy. [PMID:41747943]	Kabuta C, Hakuno F, Kataoka N, Takahashi	Neurochem Int	2026	0
An update on the monogenic causes of Parkinson's disease: Impact on patient stra [PMID:41759745]	Asmi S, Krishnan A, Alexander SM, Mohame	Ageing Res Rev	2026	0
N-acetyl-l-leucine lowers α-synuclein levels and improves synaptic function in P [PMID:41766663]	Song P, Chen C, Franchini R, Duong B, Wa	J Clin Invest	2026	0
Genome editing in Parkinson's disease: Unlocking therapeutic avenues through CRI [PMID:41905621]	["Singh R", "Maity P", "Jaiswal C"]	Neurochemistry international	2026	0

Debates (10)

Multi-agent debates referencing this entity

SNCA

Understanding Entity Pages

Summary

Wiki Pages (12)

SNCA — Alpha-Synuclein

SNCA→Alpha-synuclein→Aggregation→Lewy Bodies→Synucleinopathies Causal Chain

SNCA A53T

SNCA-A53T Alpha-Synuclein Neurons

SNCA→Alpha-synuclein→Parkinson's Disease Causal Chain

CRISPRi Epigenetic Silencing of SNCA for Parkinson's Disease

Pathway Diagram

Outgoing (1540)

Incoming (1527)

Targeting Hypotheses (3)

Mentioning Analyses (9)

How does engineered C. butyricum cross the blood-brain barrier to directly bind

Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

What determines the specificity of DDR protein recruitment to dilncRNA-induced c

Which cell types show the most significant expression changes for neurodegenerat

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Digital biomarkers and AI-driven early detection of neurodegeneration

4R-tau strain-specific spreading patterns in PSP vs CBD

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Experiments (6)

Related Papers (12)

Debates (10)

The abstract claims C. butyricum-GLP-1 crosses the BBB and binds to GLP-1 recept

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

While the study shows 53BP1 forms phase-separated foci driven by dilncRNAs, it's

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

Can speech, gait, retinal imaging, sleep, and smartphone data detect neurodegene

The debate mentioned gene expression profiling but did not specify which neural

Cell-type specific expression patterns of neurodegeneration genes in SEA-AD

What are the mechanisms underlying what are the mechanisms by which gut microbio

SNCA

Understanding Entity Pages

Summary

Wiki Pages (12)

SNCA — Alpha-Synuclein

SNCA→Alpha-synuclein→Aggregation→Lewy Bodies→Synucleinopathies Causal Chain

SNCA A53T

SNCA-A53T Alpha-Synuclein Neurons

SNCA→Alpha-synuclein→Parkinson's Disease Causal Chain

CRISPRi Epigenetic Silencing of SNCA for Parkinson's Disease

SNCAG — Synuclein Gamma

SNCAIP Gene

SNCA — Alpha-Synuclein Gene Entity Page

SNCA Gene Variants and Mutations

SNCAIP Protein

SNCA-Overexpressing Dopaminergic Neurons

Pathway Diagram

Outgoing (1540)

Incoming (1527)

Targeting Hypotheses (3)

Mentioning Analyses (9)

How does engineered C. butyricum cross the blood-brain barrier to directly bind

Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

What determines the specificity of DDR protein recruitment to dilncRNA-induced c

Which cell types show the most significant expression changes for neurodegenerat

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Digital biomarkers and AI-driven early detection of neurodegeneration

4R-tau strain-specific spreading patterns in PSP vs CBD

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's

Experiments (6)

Related Papers (12)

Debates (10)

The abstract claims C. butyricum-GLP-1 crosses the BBB and binds to GLP-1 recept

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

Do bacterial curli amyloids cross the blood-brain barrier to directly seed α-syn

Does reduced Prevotellaceae abundance cause PD pathology or result from it?

While the study shows 53BP1 forms phase-separated foci driven by dilncRNAs, it's

PSP and CBD both involve 4R-tau but produce distinct neuropathological patterns

Can speech, gait, retinal imaging, sleep, and smartphone data detect neurodegene

The debate mentioned gene expression profiling but did not specify which neural

Cell-type specific expression patterns of neurodegeneration genes in SEA-AD

What are the mechanisms underlying what are the mechanisms by which gut microbio